Moreover, postmenopausal breast cancer patients receiving ZA+neo-adjuvant chemotherapy (CT) show a significant fall in serum follistatin levels compared to CT alone, thus increasing activin's bioavailability in these patients (an effect not seen in premenopausal patients) [19]. This evidence concerns the gene INHBE and breast carcinoma.